• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

Columvi Combo Enhances Survival Outcomes in R/R Lymphoma Subgroup

by MM360 Staff | Jun 5, 2025 | Uncategorized

Source: CureToday articles Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma. Read More

Study: Maternal Asthma Increases Incidence of Adverse Perinatal Outcomes

by MM360 Staff | Jun 5, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

ASCO 2025: Insights on NALIRIFOX Use in Metastatic Pancreatic Ductal Adenocarcinoma From the NAPOLI-3 Trial

by MM360 Staff | Jun 5, 2025 | Myeloma News

Source: Pharmacy Times articles Vincent Chung, MD, discusses key findings from the NAPOLI-3 trial and offers guidance for pharmacists on managing toxicities, adjusting dosing, and supporting patients receiving NALIRIFOX for metastatic pancreatic ductal adenocarcinoma....

Iopofosine-131 Earns FDA Breakthrough for Waldenstrom Macroglobulinemia

by MM360 Staff | Jun 5, 2025 | Uncategorized

Source: CureToday articles Iopofosine-131 received FDA breakthrough status for relapsed or refractory Waldenstrom macroglobulinemia, showing strong response rates in early trials. Read More

Pharmacists Should Be Recommending Penicillin Allergy Testing

by MM360 Staff | Jun 5, 2025 | Myeloma News

Source: Pharmacy Times articles About 10% of patients report a penicillin allergy, but only around 1% are truly allergic. Recommending penicillin allergy testing can help patients determine whether they have a true allergy. Read More
« Older Entries
Next Entries »

Recent Content

  • To Combat Medication Errors, Proper Pharmacy Inventory Counts Are Essential
  • Targeted Screening Tools Can Increase Pneumococcal Vaccine Uptake in Health-System Retail Pharmacies
  • Study Finds Vitamin D3 Supplementation Reduces Telomere Attrition
  • Vadadustat and Darbepoetin Alfa Show Similar Safety, Efficacy in Patients With NDD-CKD and DD-CKD
  • Being in the Present Moment With Multiple Myeloma
  • Columvi Combo Enhances Survival Outcomes in R/R Lymphoma Subgroup
  • Study: Maternal Asthma Increases Incidence of Adverse Perinatal Outcomes
  • ASCO 2025: Insights on NALIRIFOX Use in Metastatic Pancreatic Ductal Adenocarcinoma From the NAPOLI-3 Trial
  • Iopofosine-131 Earns FDA Breakthrough for Waldenstrom Macroglobulinemia
  • Pharmacists Should Be Recommending Penicillin Allergy Testing
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT